MX2007004597A - Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion. - Google Patents
Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion.Info
- Publication number
- MX2007004597A MX2007004597A MX2007004597A MX2007004597A MX2007004597A MX 2007004597 A MX2007004597 A MX 2007004597A MX 2007004597 A MX2007004597 A MX 2007004597A MX 2007004597 A MX2007004597 A MX 2007004597A MX 2007004597 A MX2007004597 A MX 2007004597A
- Authority
- MX
- Mexico
- Prior art keywords
- zcytor21
- antibodies
- binding partners
- soluble
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
Abstract
La presente invencion se refiere a antagonistas ZcytoR21, tales como receptor soluble y anticuerpos anti-ZcytoR21, que son utiles para bloquear, inhibir, reducir, antagonizar o neutralizar la actividad de IL-17C. La IL-17C es una citoquina que esta involucrada en procesos inflamatorios y de enfermedad humana. El ZcytoR21 es un receptor para IL-17C. La presente invencion incluye ZcytoR21, soluble, anticuerpos anti-ZcytoR21 y moleculas de enlace, asi como metodos para antagonizar IL-17C usando tales receptores solubles, anticuerpos y moleculas de enlace.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61965104P | 2004-10-18 | 2004-10-18 | |
US62220704P | 2004-10-25 | 2004-10-25 | |
PCT/US2005/037332 WO2006044840A2 (en) | 2004-10-18 | 2005-10-18 | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007004597A true MX2007004597A (es) | 2007-06-22 |
Family
ID=36090952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007004597A MX2007004597A (es) | 2004-10-18 | 2005-10-18 | Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20060142192A1 (es) |
EP (1) | EP1802657A2 (es) |
JP (1) | JP2008516985A (es) |
KR (1) | KR20070084330A (es) |
AU (1) | AU2005295421A1 (es) |
BR (1) | BRPI0516603A (es) |
CA (1) | CA2584078A1 (es) |
EA (1) | EA200700823A1 (es) |
IL (1) | IL182186A0 (es) |
MX (1) | MX2007004597A (es) |
NO (1) | NO20072514L (es) |
WO (1) | WO2006044840A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
CA2584078A1 (en) * | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
EP1931708A1 (en) * | 2005-10-18 | 2008-06-18 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
EP2064237A2 (en) * | 2006-10-18 | 2009-06-03 | ZymoGenetics, Inc. | Il-17c antagonists and methods of using the same |
PL2768859T3 (pl) * | 2011-10-19 | 2018-07-31 | Morphosys Ag | Antagoniści IL17C do leczenia zaburzeń zapalnych |
JP2018529704A (ja) * | 2015-10-05 | 2018-10-11 | モルフォシス・アーゲー | アトピー性皮膚炎の治療および/または予防のためのil−17cの拮抗剤 |
CU20180087A7 (es) | 2016-02-19 | 2019-03-04 | Galapagos Nv | Anticuerpos para il-17-c |
EP4352217A1 (en) * | 2021-06-10 | 2024-04-17 | Janssen Biotech, Inc. | Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0817847B2 (en) * | 1995-03-23 | 2009-09-09 | Immunex Corporation | Il-17 receptor |
US6579520B2 (en) * | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US20020177188A1 (en) * | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6569645B2 (en) * | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
MXPA02011617A (es) * | 2000-05-24 | 2003-03-10 | Schering Corp | Proteinas de mamiferos receptoras, reactivosy metodos relacionados. |
US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
US20030096969A1 (en) * | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2005508615A (ja) * | 2001-07-09 | 2005-04-07 | ザイモジェネティクス,インコーポレイティド | ヒトサイトカイン受容体 |
CA2584078A1 (en) * | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
EP1931708A1 (en) * | 2005-10-18 | 2008-06-18 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
-
2005
- 2005-10-18 CA CA002584078A patent/CA2584078A1/en not_active Abandoned
- 2005-10-18 EA EA200700823A patent/EA200700823A1/ru unknown
- 2005-10-18 EP EP05818898A patent/EP1802657A2/en not_active Withdrawn
- 2005-10-18 JP JP2007537014A patent/JP2008516985A/ja active Pending
- 2005-10-18 BR BRPI0516603-9A patent/BRPI0516603A/pt not_active IP Right Cessation
- 2005-10-18 MX MX2007004597A patent/MX2007004597A/es not_active Application Discontinuation
- 2005-10-18 AU AU2005295421A patent/AU2005295421A1/en not_active Abandoned
- 2005-10-18 WO PCT/US2005/037332 patent/WO2006044840A2/en active Application Filing
- 2005-10-18 KR KR1020077011257A patent/KR20070084330A/ko not_active Application Discontinuation
- 2005-10-18 US US11/253,200 patent/US20060142192A1/en not_active Abandoned
-
2006
- 2006-10-04 US US11/538,561 patent/US20070049525A1/en not_active Abandoned
- 2006-10-04 US US11/538,549 patent/US20070049524A1/en not_active Abandoned
-
2007
- 2007-03-26 IL IL182186A patent/IL182186A0/en unknown
- 2007-05-16 NO NO20072514A patent/NO20072514L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200700823A1 (ru) | 2008-02-28 |
US20060142192A1 (en) | 2006-06-29 |
IL182186A0 (en) | 2007-07-24 |
EP1802657A2 (en) | 2007-07-04 |
KR20070084330A (ko) | 2007-08-24 |
WO2006044840A8 (en) | 2006-07-06 |
BRPI0516603A (pt) | 2008-09-16 |
US20070049525A1 (en) | 2007-03-01 |
JP2008516985A (ja) | 2008-05-22 |
WO2006044840A2 (en) | 2006-04-27 |
NO20072514L (no) | 2007-07-17 |
CA2584078A1 (en) | 2006-04-27 |
US20070049524A1 (en) | 2007-03-01 |
AU2005295421A1 (en) | 2006-04-27 |
WO2006044840A3 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06014465A (es) | Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion. | |
WO2008049070A3 (en) | Il-17c antagonists and methods of using the same | |
MX2007004597A (es) | Zcytor21 soluble, anticuerpos anti-zcytor21 y moleculas de enlace y metodos de uso en inflamacion. | |
IL189726A0 (en) | Il-17a and il-17f antagonists and methods of using the same | |
ZA200704125B (en) | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation | |
ATE475673T1 (de) | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung | |
WO2005052001A3 (en) | Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation | |
WO2007106769A3 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
MY146986A (en) | Methods for treating interleukin-6 related diseases | |
IL192950A0 (en) | Soluble il-17rcx4 and methods of using in inflammation | |
TW200517126A (en) | Mesothelioma therapeutic agent | |
PL2322556T3 (pl) | Humanizowani antagoniści anty-beta7 i ich zastosowania | |
WO2006086396A3 (en) | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation | |
WO2004042009A3 (en) | Inhibition of il-17 production | |
ZA200806610B (en) | Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6ralpha to GP130 | |
ZA200701656B (en) | Humanized anti-cment antagonists | |
WO2008133684A8 (en) | Antibodies that bind both il-17a and il-17f and methods of using the same | |
WO2007033140A3 (en) | Prok2 antagonists and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |